AbbVie Will Use Allergan Revenue To Fund Combined Firm's Large R&D Pipeline

 
• By Mandy Jackson

While AbbVie said its $63bn purchase places little value on Allergan's R&D pipeline, the companies have 62 drugs in clinical development with 38 in Phase II and III or filed with regulators, including new indications for approved products.

R&D
Botox and other Allergan products will fund AbbVie's diversification. • Source: Shutterstock

More from Deals

More from Business